biolog
process
articl
highlight
integr
role
vesicular
traffick
play
lung
cell
biolog
relat
maintain
effici
respir
surfact
secret
reuptak
mainten
intact
alveolarcapillari
barrier
prevent
mechan
forceinduc
cell
injuri
defect
traffick
machineri
result
specif
respiratori
diseas
respiratori
virus
includ
rhinovirus
enterovirus
picornavirida
influenza
virus
orthomyxovirida
parainfluenza
metapneumovirus
respiratori
syncyti
virus
paramyxovirida
coronavirus
coronavirida
sever
adenovirus
except
adenovirus
possess
rna
genom
usual
transmit
direct
hand
surfac
hand
contact
andor
aerosol
inhal
replic
upper
lower
airway
cellular
humor
immun
activ
respons
respiratori
viral
infect
well
neural
pathway
contribut
distant
inflammatori
effect
respiratori
virus
respons
wide
varieti
clinic
syndrom
includ
common
cold
acut
otiti
media
laryng
sinus
pneumonia
bronchiol
influenza
exacerb
asthma
chronic
obstruct
pulmonari
diseas
diagnosi
respiratori
viral
infect
primarili
clinic
support
laboratori
techniqu
antigen
detect
cultur
serolog
recent
nucleic
acid
detect
prevent
strategi
base
avoid
risk
factor
vaccin
indic
treatment
modal
includ
overthecount
nonspecif
remedi
along
small
number
specif
antivir
medic
influenza
neuraminidas
inhibitor
human
rhinovirus
rv
probabl
repres
abund
pathogen
microorgan
univers
rna
virus
belong
famili
picornavirida
picornavirida
also
includ
enterovirus
polio
coxsacki
echo
virus
close
relat
rv
cardioand
aphthovirus
infect
respiratori
tract
coxsacki
viru
echoviru
type
frequent
isol
enterovir
agent
upper
respiratori
tract
infect
serotyp
rv
identifi
number
divid
major
minor
group
depend
receptor
major
rv
attach
intercellular
adhes
lowdens
lipoprotein
receptor
cellular
receptor
minor
rv
rv
consist
mda
singlestrand
positivesens
genom
rna
surround
nonenvelop
capsid
arrang
icosahedron
nm
diamet
figur
structur
protein
viru
highli
variabl
surfac
protein
interact
antivir
antibodi
confin
interior
capsid
close
associ
viral
rna
orthomyxovirida
major
repres
influenza
virus
ifv
group
three
type
b
c
ifv
negativestrand
segment
rna
virus
b
type
envelop
pleomorph
agent
spheric
filament
form
ifvc
structur
distinct
ifv
attach
sialic
acid
receptor
ciliat
columnar
epitheli
cell
tracheobronchi
tree
via
hemagglutinin
ha
protein
figur
follow
replic
virion
releas
enzymat
action
neuraminidas
na
surfac
protein
latter
along
ha
protein
viru
regularli
subject
small
chang
capabl
produc
viral
strain
caus
annual
epidem
phenomenon
call
antigen
drift
antigen
shift
process
sudden
major
chang
ha
na
protein
ifva
occur
due
genet
reassort
latter
respons
influenza
pandem
occur
everi
year
paramyxovirida
includ
parainfluenza
virus
piv
respiratori
syncyti
virus
rsv
well
recent
identifi
human
metapneumoviru
hmpv
piv
group
subtyp
belong
paramyxoviru
genu
subtyp
belong
rubella
viru
genu
along
mump
viru
piv
singlestrand
negativesens
rna
virus
nm
diamet
helic
nucleocapsid
contrast
rsv
piv
possess
ha
na
protein
attach
sialic
acid
receptor
rsv
pleomorph
envelop
virus
nm
diamet
nonseg
negativesens
rna
genom
two
subtyp
b
viral
genom
encod
glycosyl
f
fusion
g
attach
protein
among
other
former
contribut
agent
infect
virul
latter
involv
viruscel
cellcel
fusion
exhibit
high
variabl
among
differ
serogroup
mpv
recent
identifi
paramyxoviruslik
pleomorph
agent
rna
virus
two
potenti
subgroup
distinguish
human
coronavirus
cv
belong
coronavirida
envelop
roughli
spheric
virus
nm
diamet
nmlong
round
surfac
project
genom
consist
posit
rna
strand
cv
studi
far
close
relat
one
two
refer
strain
domin
outbreak
altern
year
year
former
bind
mhc
class
molecul
latter
bind
human
aminopeptidas
n
sarscov
anoth
recent
identifi
cv
differ
phylogenet
known
human
cv
adenovirus
nonenvelop
singlestrand
dna
virus
genom
kbp
encod
structur
protein
surround
capsid
icosahedr
symmetri
stalklik
structur
protrud
call
fiber
figur
latter
interact
variou
cellular
receptor
mhc
class
molecul
coxsackieadenoviru
receptor
serotyp
six
subgenera
af
identifi
rv
transmit
direct
hand
surfac
hand
contact
aerosol
inhal
frequent
rsv
eye
nose
mouth
nasal
epithelium
repres
primari
site
infect
virus
rv
replic
mainli
nose
although
replic
take
place
lower
airway
well
ifv
usual
transmit
inhal
droplet
initi
attach
mucou
layer
cover
tracheobronchi
tree
replic
primarili
lower
respiratori
tract
epitheli
infect
rv
patchi
distribut
overtli
cytotox
contrast
major
respiratori
virus
includ
ifv
paramyxovirus
adenovirus
caus
extens
inflamm
epitheli
shed
respiratori
viru
infect
caus
increas
vascular
permeabl
mediat
vasoact
amin
glandular
secret
influenc
cholinerg
reflex
neuropeptid
sever
cytokin
chemokin
also
implic
virusinduc
inflamm
inflammatori
cell
aggrav
event
releas
addit
mediat
humor
immun
also
activ
respons
viral
infect
product
serotypespecif
antibodi
natur
respons
associ
age
previou
infect
vaccin
statu
host
recoveri
respiratori
viral
ill
usual
achiev
prior
detect
specif
antibodi
indic
cellular
andor
nonspecif
immun
respons
primarili
respons
viral
erad
nevertheless
antibodi
abl
provid
protect
secondari
infect
respiratori
virus
induc
local
inflammatori
reaction
level
infect
epitheli
cell
may
also
act
distanc
neuron
pathway
parasympathet
sympathet
nonadrenerg
noncholinerg
nervou
suppli
respiratori
tree
may
affect
viral
infect
suggest
import
neuroimmun
interact
may
contribut
virusmedi
reactiv
airway
diseas
figur
respiratori
virus
relat
variou
distinct
well
nonspecif
clinic
present
consider
overlap
virus
clinic
present
although
differ
exist
agent
may
caus
sever
clinic
syndrom
tabl
among
common
cold
far
commonest
enorm
socioeconom
impact
clinic
present
rang
asymptomat
upper
respiratori
tract
urt
symptom
nasal
congest
rhinorrhea
nasopharyng
irrit
lower
respiratori
tract
symptom
cough
system
symptom
includ
gener
malais
headach
sleep
impair
depend
viral
culprit
host
incub
period
h
symptom
usual
last
day
common
cold
rather
benign
clinic
entiti
may
howev
complic
secondari
bacteri
infect
otiti
media
sinus
pneumonia
asthma
exacerb
death
may
occur
immunocompromis
patient
viral
urt
infect
often
result
impair
function
eustachian
tube
predispos
develop
acut
otiti
media
latter
one
commonest
infect
among
children
often
attribut
viral
etiolog
respiratori
virus
may
also
predispos
nasopharyng
bacteri
colon
alter
host
immun
respons
final
virus
may
respons
antibiot
treatment
failur
case
concurr
bacteri
viral
infect
likewis
respiratori
virus
implic
develop
sinus
either
directli
extens
urt
infect
result
secondari
bacteri
infect
laryng
laryngotracheobronchitiscroup
frequent
associ
parainfluenza
viru
group
pneumonia
infant
young
children
commonli
attribut
virus
diseas
burden
also
signific
among
elderli
immunocompromis
rv
rsv
agent
frequent
isol
viral
pneumonia
although
age
season
year
variat
consider
presenc
adenoviru
risk
factor
sever
diseas
infant
influenza
occur
yearli
winter
epidem
pandem
everi
year
result
enorm
morbid
mortal
especi
among
young
elderli
immunocompromis
rsv
also
major
pathogen
implic
acut
bronchiol
afflict
infant
respons
great
number
hospit
death
age
group
host
immun
respons
skew
toward
type
cytokin
product
seem
play
central
role
pathogenesi
diseas
bronchiol
associ
recurr
wheez
great
major
acut
asthma
exacerb
children
consider
proport
adult
preced
viral
urt
infect
exacerb
may
often
result
hospit
frequent
isol
offend
agent
rv
fact
reflect
preponder
viru
among
common
cold
case
final
exacerb
chronic
obstruct
pulmonari
diseas
may
also
viral
etiolog
commonli
due
rv
diagnosi
respiratori
viral
infect
reli
upon
clinic
criteria
support
laboratori
techniqu
direct
viral
nucleic
acid
antigen
detect
cultur
serolog
direct
detect
base
identif
whole
viru
inclus
bodi
electron
light
microscopi
respect
viral
antigen
may
also
detect
use
immunofluoresc
enzym
immunoassay
adequ
viral
load
requir
viral
cultur
usual
demonstr
biolog
effect
agent
cytopath
effect
hemagglutin
cultur
cell
cultur
figur
pathogenesi
respiratori
viral
infect
respiratori
virus
enter
human
bodi
mainli
nose
thereaft
replic
nasopharyng
epitheli
cell
also
lower
respiratori
tract
immun
mediat
cytokin
chemokin
bradykinin
elicit
immun
respons
lead
effect
viru
erad
contribut
develop
associ
symptomatolog
vascular
leakag
increas
glandular
secret
neurogen
pathway
also
involv
develop
clinic
manifest
reproduc
permiss
dr
n
g
papadopoulo
method
howev
drawback
due
low
sensit
extens
time
length
day
week
determin
specif
viral
antibodi
host
blood
sampl
comparison
acut
convalesc
phase
respiratori
ill
anoth
diagnost
modal
mainli
use
epidemiolog
purpos
serolog
test
includ
immunoassay
complement
fixat
passiv
agglutin
assay
well
hemagglutin
inhibit
polymeras
chain
reaction
pcr
base
techniqu
develop
replac
sever
instanc
techniqu
rapid
sensit
may
also
provid
estim
number
viral
copi
present
given
biolog
sampl
realtim
pcr
control
transmiss
respiratori
infect
may
partli
achiev
adequ
hygien
practic
avoid
congreg
stress
develop
effect
vaccin
hamper
larg
number
viral
serotyp
howev
vaccin
avail
ifv
sever
rsv
piv
vaccin
candid
current
clinic
investig
oral
live
attenu
adenoviru
vaccin
success
use
militari
recruit
center
past
overthecount
remedi
allevi
reduct
durat
common
cold
symptom
includ
vitamin
c
zinc
echinacea
although
agent
moder
effect
nasal
decongest
first
gener
antihistamin
anticholinerg
nasal
spray
oral
intranas
aadrenerg
agonist
inhal
humidifi
hot
air
nonsteroid
antiinflammatori
drug
cromon
propos
symptomat
relief
moder
result
combin
specif
antivir
one
antiinflammatori
drug
may
offer
ideal
therapeut
approach
sinc
would
inhibit
viral
replic
block
inflammatori
event
although
cost
complianc
consider
obstacl
unfortun
limit
number
antivir
agent
avail
respiratori
virus
due
frequent
mutat
result
constant
emerg
new
often
resist
strain
specif
antivir
chemotherapi
exist
ifv
form
classic
adamantan
amantadin
rimantadin
well
new
na
inhibitor
zanamivir
intranas
formul
oseltamivir
former
effect
ifv
signific
advers
effect
often
result
develop
resist
strain
contrast
latter
activ
b
ifv
possess
minim
advers
effect
current
indic
prophylact
therapeut
purpos
palivizumab
monoclon
antibodi
rsv
may
administ
prophylact
infant
high
risk
sever
bronchiol
ribavirin
antivir
agent
current
less
frequent
use
effect
compound
varieti
respiratori
virus
result
common
cold
interferon
administ
intranas
shortli
exposur
howev
due
high
cost
dosag
frequenc
six
time
daili
side
effect
mainli
nasal
irrit
bleed
clinic
applic
abandon
sever
agent
assess
activ
rhinovirus
pleconaril
oral
agent
bind
capsid
protein
picornavirus
thu
inhibit
capsid
function
viral
attach
cellular
receptor
viral
uncoat
ruprintivir
welltoler
irrevers
inhibitor
picornaviru
proteas
report
advers
effect
usual
restrict
bloodting
mucu
nasal
passag
irrit
compound
current
clinic
trial
